Tetmyb Vaccine
Adenoid Cystic Carcinoma
Peter MacCallum Cancer Centre, AustraliavaccinePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Adenoid Cystic Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab Fox Chase Cancer Center | Phase 1/2 | B |
Irinotecan National Cancer Institute (NCI) | Phase 1/2 | B |
VIPIVOTIDE TETRAXETAN Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 | CCC |
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | CCC |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
View all 28 →
Same molecule, other indications
Tetmyb Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →